Atrium Therapeutics recruiting for Phase 1/2 ATR 1072 trial in PRKAG2 Syndrome
Atrium Therapeutics is enrolling adults with PRKAG2 Syndrome in a first-in-human study of its siRNA conjugate ATR 1072, with about 37 participants planned.
Atrium Therapeutics' single active trial this week concerns its investigational cardiac therapy ATR 1072.
- ATR 1072, an antibody-oligonucleotide conjugate designed to reduce PRKAG2 gene expression, is being tested in a Phase 1/2 open-label study for adults with PRKAG2 Syndrome. ATR 1072 is an antibody-oligonucleotide conjugate (AOC) designed to reduce expression of PRKAG2 through targeted delivery of siRNA to cardiac tissue, and this first-in-human, Phase 1/2, open-label, multicenter study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of multiple doses of ATR 1072 in adults with PRKAG2 Syndrome.1 The trial is recruiting, with an actual start date of September 14, 2026, and the record was last updated September 18, 2026. Approximately 37 participants will be enrolled globally.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.